Ironwood Pharmaceuticals Inc (IRWD)-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:Ironwood Pharmaceuticals Inc (IRWD) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8012204
◆発行会社(調査会社):GlobalData
◆発行日:2017年12月14日
◆ページ数:71
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Ironwood Pharmaceuticals Inc (Ironwood) is a commercial biotechnology company that discovers, develops and commercializes medicines for gastrointestinal (GI) disorders. The company’s marketed products consist of Linzess (linaclotide), an oral capsule for the treatment of irritable bowel syndrome with constipation or chronic idiopathic constipation in adult men and women; and Zurampic (lesinurad) for the treatment of hyperuricemia associated with gout. Ironwood also evaluates linaclotide in other indications, new formulations and in combination with other products in various GI conditions. Its pipeline product portfolio comprises Duzallo (lesinurad and allopurinol), a combination product for the treatment of hyperuricemia in patients with uncontrolled gout; and other development programs. Ironwood is headquartered in Cambridge, Massachusetts, the US.

Ironwood Pharmaceuticals Inc (IRWD) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12
Partnerships 12
Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 12
Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 13
AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 14
AstraZeneca Enters Into Co-Promotion Agreement With Ironwood Pharma For Nexium 16
Ironwood Pharma Enters Into Collaboration With Protagonist Therapeutics 17
Licensing Agreements 18
Ironwood Pharma Enters into Licensing Agreement with AstraZeneca 18
Ironwood Pharma Enters Into Licensing Agreement With Depomed 19
Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 20
Equity Offering 21
Ironwood Pharma Plans to Raise Funds through Public Offering of Securities 21
Ironwood Pharma Raises USD201.3 Million in Public Offering of Shares 22
Ironwood Pharma Completes Partial Exercise Of Underwriter’s Option For Public Offering Of Shares For US$146 Million 24
Ironwood Pharma Completes Public Offering Of Common Stock For US$91 Million 26
Debt Offering 28
Ironwood Pharma Raises USD150 Million in Private Placement of 8.375% Notes Due 2026 28
Ironwood Pharma Raises USD335.7 Million in Private Placement of 2.25% Notes Due 2022 29
Ironwood Pharma Completes Private Placement Of Notes Due 2024 For US$175 Million 30
Ironwood Pharmaceuticals Inc – Key Competitors 31
Ironwood Pharmaceuticals Inc – Key Employees 32
Ironwood Pharmaceuticals Inc – Locations And Subsidiaries 33
Head Office 33
Other Locations & Subsidiaries 33
Recent Developments 34
Financial Announcements 34
Nov 02, 2017: Ironwood Pharmaceuticals Provides Third Quarter 2017 Investor Update 34
Aug 03, 2017: Ironwood Pharmaceuticals Provides Second Quarter 2017 Investor Update 39
May 08, 2017: Ironwood Pharmaceuticals Provides First Quarter 2017 Investor Update 41
Feb 21, 2017: Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2016 Investor Update 43
Nov 03, 2016: Ironwood Pharmaceuticals Provides Third Quarter 2016 Investor Update 47
Aug 04, 2016: Ironwood Pharmaceuticals Provides Second Quarter 2016 Investor Update 50
May 09, 2016: Ironwood Pharmaceuticals Provides First Quarter 2016 Investor Update 54
Feb 18, 2016: Ironwood Pharmaceuticals Provides Fourth Quarter and Full Year 2015 Investor Update 57
Corporate Communications 60
Nov 28, 2017: Ironwood Pharmaceuticals Strengthens Executive Leadership Team 60
Sep 06, 2017: Ironwood Pharmaceuticals Announces Leadership Change 61
Apr 06, 2017: Ironwood Pharmaceuticals Appoints Dr. Christopher Wright as Senior Vice President of Global Development and Chief Development Officer 62
Jan 04, 2017: Ironwood Pharmaceuticals Appoints Amy Schulman to Board of Directors 63
Apr 07, 2016: Ironwood Pharmaceuticals Appoints Andrew Dreyfus to Board of Directors 64
Product News 65
03/30/2016: Ironwood Pharmaceuticals to Present Clinical Data on sGC Stimulator IW-1973 at Upcoming Scientific Conferences 65
01/15/2016: Link Between Obesity and Increased Risk of Colorectal Cancer Revealed 66
Clinical Trials 68
Feb 18, 2016: Ironwood Pharmaceuticals Progresses Vascular and Fibrotic Disease Platform with Positive Top-Line Phase Ia Data on Soluble Guanylate Cyclase Stimulator IW-1701 68
Other Significant Developments 69
Jan 08, 2017: Ironwood Pharmaceuticals Demonstrates Strong Execution on Strategy to Build Top-Performing Commercial Biotech 69
Appendix 71
Methodology 71
About GlobalData 71
Contact Us 71
Disclaimer 71

List of Tables
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2015 2
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
Ironwood Pharmaceuticals Inc, Deals By Therapy Area, 2011 to YTD 2017 9
Ironwood Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Ironwood Pharma Enters into Co-Promotion Agreement with Allergan 12
Ironwood Pharma And Protagonist Therapeutics Expand Peptide Drug Discovery Collaboration 13
AstraZeneca Enters Into Co-Development Agreement With Ironwood Pharma For Linaclotide 14
AstraZeneca Enters Into Co-Promotion Agreement With Ironwood Pharma For Nexium 16
Ironwood Pharma Enters Into Collaboration With Protagonist Therapeutics 17
Ironwood Pharma Enters into Licensing Agreement with AstraZeneca 18
Ironwood Pharma Enters Into Licensing Agreement With Depomed 19
Synergy Pharma Enters Into Agreement With Ironwood Pharma For Plecanatide 20
Ironwood Pharma Plans to Raise Funds through Public Offering of Securities 21
Ironwood Pharma Raises USD201.3 Million in Public Offering of Shares 22
Ironwood Pharma Completes Partial Exercise Of Underwriter's Option For Public Offering Of Shares For US$146 Million 24
Ironwood Pharma Completes Public Offering Of Common Stock For US$91 Million 26
Ironwood Pharma Raises USD150 Million in Private Placement of 8.375% Notes Due 2026 28
Ironwood Pharma Raises USD335.7 Million in Private Placement of 2.25% Notes Due 2022 29
Ironwood Pharma Completes Private Placement Of Notes Due 2024 For US$175 Million 30
Ironwood Pharmaceuticals Inc, Key Competitors 31
Ironwood Pharmaceuticals Inc, Key Employees 32
Ironwood Pharmaceuticals Inc, Subsidiaries 33

★海外企業調査レポート[Ironwood Pharmaceuticals Inc (IRWD)-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Bonjour Holdings Limited:企業の戦略・SWOT・財務情報
    Bonjour Holdings Limited - Strategy, SWOT and Corporate Finance Report Summary Bonjour Holdings Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service o …
  • Delta Electricity:企業の戦略的SWOT分析
    Delta Electricity - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and serv …
  • AMAG Austria Metall AG:企業の戦略・SWOT・財務情報
    AMAG Austria Metall AG - Strategy, SWOT and Corporate Finance Report Summary AMAG Austria Metall AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offer …
  • Vascutek Ltd:製品パイプライン分析
    Summary Vascutek Ltd (Vascutek), a subsidiary of Terumo Corp is a medical equipment company that designs, manufactures and distributes vascular and cardiovascular products. The company provides products such as stent graft system, aortic root designs, polyester products and EPTFE products, among oth …
  • Euromoney Institutional Investor PLC:企業の戦略・SWOT・財務分析
    Euromoney Institutional Investor PLC - Strategy, SWOT and Corporate Finance Report Summary Euromoney Institutional Investor PLC - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysi …
  • DPL Inc:企業の戦略的SWOT分析
    DPL Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. This …
  • Sam Chun Dang Pharm Co Ltd (000250)-製薬・医療分野:企業M&A・提携分析
    Summary Sam Chun Dang Pharm Co Ltd (SCD) is a research and development company that discovers and develops drugs. The company offers products in the therapeutic areas of ophthalmology, cardiovasculars, endocrinology, gastrointestines, antibacterials, anti-fungals, antivirals, respiratory, antiinflam …
  • Interconexion Electrica S.A. E.S.P.:発電所・企業SWOT分析
    Interconexion Electrica S.A. E.S.P. - Power Plants and SWOT Analysis, 2017 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information …
  • Q BioMed Inc (QBIO):製薬・医療:M&Aディール及び事業提携情報
    Summary Q BioMed Inc (Q BioMed), formerly ISMO Tech Solutions Inc, is a biomedical acceleration and development company. The company offers Strontium Chloride SR89, a radiopharmaceutical agent for the treatment of pain associated with metastatic bone cancer. It develops Man-01, a pre-clinical lead c …
  • Sparton Resources Inc (SRI):企業の財務・戦略的SWOT分析
    Summary Sparton Resources Inc (Sparton Resources) is a diversified company that acquires and develops oil and gas properties in North America and China. The company’s products portfolio includes vanadium, natural gas, crude oil, gold, and vanadium flow batteries, among others. Its energy projects co …
  • Dataprep Holdings Berhad (DATAPRP):企業の財務・戦略的SWOT分析
    Dataprep Holdings Berhad (DATAPRP) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and w …
  • NeuStar Inc:企業の戦略的SWOT分析
    NeuStar Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. …
  • XALT Energy LLC:企業の戦略的SWOT分析
    XALT Energy LLC - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and servic …
  • Adaptive Biotechnologies Corp:製薬・医療:M&Aディール及び事業提携情報
    Summary Adaptive Biotechnologies Corp (Adaptive) specializes in combining high-throughput sequencing and expert bioinformatics to profile T-cell and B-cell receptors. The company’s product portfolio comprises immunoSEQ and clonoSEQ. It provides immunosequencing platform to laboratories for conductin …
  • Yanmar Co Ltd:企業の戦略的SWOT分析
    Yanmar Co Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services …
  • Synthetic Genomics Inc-製薬・医療分野:企業M&A・提携分析
    Summary Synthetic Genomics Inc (Synthetic Genomics) is a provider of synthetic biology and synthetic genomics solutions. The company offers DNA synthesis services, instrumentation, reagents, and bioinformatics services and software packages. It offers solutions in genomics research, bioproduction, a …
  • Coca-Cola Icecek A.S.:戦略・SWOT・企業財務分析
    Coca-Cola Icecek A.S. - Strategy, SWOT and Corporate Finance Report Summary Coca-Cola Icecek A.S. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Big Rivers Electric Corporation:企業の発電所・SWOT分析2018
    Big Rivers Electric Corporation - Power Plants and SWOT Analysis, 2018 Update Summary The report contains a detailed description of the power generation company’s business operations, history, corporate strategy, and business structure. This report contains a detailed SWOT analysis, information on k …
  • Nuverra Environmental Solutions, Inc. (NES)-石油・ガス分野:企業M&A・提携分析
    Summary Nuverra Environmental Solutions, Inc. (Nuverra), formerly known as Heckmann Corporation, provides environmental solutions to customers focused on the development and ongoing production of oil and natural gas from shale formations. It provides environmental solutions, including delivery, coll …
  • Healthcare Services Group Inc (HCSG):企業の財務・戦略的SWOT分析
    Healthcare Services Group Inc (HCSG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆